THE RELATIONSHIP BETWEEN THE IMMUNODETECTION OF TRANSFORMING GROWTH-FACTOR-BETA IN LUNG ADENOCARCINOMA AND LONGER SURVIVAL RATES

被引：14

作者：

INOUE, T

ISHIDA, T

TAKENOYAMA, M

SUGIO, K

SUGIMACHI, K

机构：

[1] Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka

来源：

SURGICAL ONCOLOGY-OXFORD | 1995年 / 4卷 / 01期

关键词：

TRANSFORMING GROWTH FACTOR-BETA; LUNG ADENOCARCINOMA;

D O I：

10.1016/S0960-7404(10)80031-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We immunohistochemically examined the expression of transforming growth factor-beta (TGF-beta) on tissue specimens from primary 124 human lung adenocarcinoma, using a polyclonal antibody. The overall mean immunoreactivity of TGF-beta was 25.7+/-22.9, therefore we separated patients into two groups according to their mean immunereactivity. There were 59 (48%) with a high TGF-beta and 65 (52%) with a low TGF-beta. No correlation was observed between the expression of TGF-beta and clinicopathological factors except for degree of differentiation. The 5-year survival rates of patients with high and low TGF-beta were 71% and 37%, respectively (P < 0.05). A multivariate analysis using the Cox life table regression model showed TGF-beta to be a significantly independent factor, We thus concluded, based on our findings, that the expression of TGF-beta was found to be related to a better prognosis. Therefore, estimating the negative cell proliferation activity induced by TGF-beta on immunohistochemical technique is considered to be useful for determining the patients' prognosis in cases of lung adenocarcinoma.

引用

页码：51 / 57

页数：7

共 24 条

[1]

Moses HL, Tucker RF, Leof EB, Et al., Type transforming growth factor is a growth stimulator and a growth inhibitor, Cancer Cells, 3, pp. 65-71, (1985)

[2]

Spore MB, Roberts AB, Wakefield LM, Et al., Some recent advances in the chemistry and biology of transforming growth factor-β, J Cell Biol, 195, pp. 1039-1045, (1987)

[3]

Yun K, Fidler AE, Eccles MR, Et al., Insulin-like growth factor II and WT1 transcript location in human fetal kidney and Wilms' tumour, Cancer Res, 53, pp. 5166-5171, (1993)

[4]

Leof EB, Proper JA, Goustin AS, Et al., Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor: A proposed model for indirect mitogenesis involving autocrine activity, Proc Natl Acad Sci USA, 83, pp. 2453-2457, (1986)

[5]

Heimark RL, Twardzik DR, Schwartz SM, Inhibition of endothelial regeneration by type-β transforming growth factor from platelets, Science, 233, pp. 1078-1080, (1986)

[6]

Zumaier G, Lippman M, Effects of TGF-β on normal and malignant mammary epithelium, Annals of the New York Academy of Sciences, 593, pp. 272-275, (1990)

[7]

Twardzig DR, Ranchalis JE, McPherson JM, Et al., Inhibition and promotion of differentiated-like phenotype of a human lung carcinoma in athymic mice by natural and recombinant forms of transforming growth factor-β, JNCI Journal of the National Cancer Institute, 81, pp. 1182-1185, (1989)

[8]

Laiho M, Decaprio JA, Ludlow JW, Et al., Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation, Cell, 62, pp. 175-185, (1990)

[9]

Derynck R, Goeddel GV, Ullrich A, Et al., Synthesis of messenger RNAs transforming growth factor-β and the epidermal growth factor receptor by human tumours, Cancer Res, 47, pp. 707-712, (1987)

[10]

Mizukami Y, Nonomura A, Yamada T, Et al., Immuno-histochemical demonstration of growth factors, TGF-alpha, TGF-β, IGF-I and neu oncogene product in benign and malignant human breast tissues, Anticancer Res, 10, pp. 1115-1126, (1990)

← 1 2 3 →